Organon & Co. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
Organon & Co. (OGN) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $1.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Goodwill and Other
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2026-07-31
- Organon & Co. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2026-06-30 was $1.00M.
- Organon & Co. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Organon & Co. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2025-12-31 was $0.00.
- Organon & Co. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Organon & Co. research and development asset acquired other than through business combination, fair value acquired for fiscal 2025 was $6.00M, a 92.59% decline from fiscal 2024.
- Organon & Co. research and development asset acquired other than through business combination, fair value acquired for fiscal 2024 was $81.00M, a 912.50% increase from fiscal 2023.
- Organon & Co. research and development asset acquired other than through business combination, fair value acquired for fiscal 2023 was $8.00M, a 92.52% decline from fiscal 2022.
- Organon & Co. research and development asset acquired other than through business combination, fair value acquired for fiscal 2022 was $107.00M, a 2.88% increase from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 3 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 6 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 9 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-07-31 | $1.00M 10-Q · filed 2026-07-31 | $1.00M derived: sum of 3 quarters · filed 2026-07-31 | $1.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-05-04 | $0.00 derived: sum of 3 quarters · filed 2026-05-04 | $0.00 derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-07-31 | $6.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-07-31 | $6.00M 10-Q · filed 2025-11-10 | $6.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-31 | $6.00M 10-Q · filed 2026-07-31 | $6.00M derived: sum of 3 quarters · filed 2026-07-31 | $57.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $6.00M 10-Q · filed 2026-05-04 | $6.00M derived: sum of 2 quarters · filed 2026-05-04 | $57.00M derived: sum of 3 quarters · filed 2026-05-04 | $72.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $51.00M derived: sum of 2 quarters · filed 2026-02-24 | $66.00M derived: sum of 3 quarters · filed 2026-02-24 | $81.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $51.00M 10-Q · filed 2025-11-10 | $66.00M derived: sum of 2 quarters · filed 2025-11-10 | $81.00M 10-Q · filed 2025-11-10 | $81.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $15.00M 10-Q · filed 2025-08-06 | $30.00M 10-Q · filed 2025-08-06 | $30.00M derived: sum of 3 quarters · filed 2026-02-24 | $30.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $15.00M 10-Q · filed 2025-05-02 | $15.00M derived: sum of 2 quarters · filed 2026-02-24 | $15.00M derived: sum of 3 quarters · filed 2026-02-24 | $15.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $8.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-01 | $0.00 derived: sum of 2 quarters · filed 2024-11-01 | $8.00M 10-Q · filed 2024-11-01 | $8.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $8.00M 10-Q · filed 2024-08-07 | $8.00M derived: sum of 3 quarters · filed 2025-11-10 | $18.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $8.00M 10-Q · filed 2024-05-03 | $8.00M derived: sum of 2 quarters · filed 2025-11-10 | $18.00M derived: sum of 3 quarters · filed 2025-11-10 | $115.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $10.00M derived: sum of 2 quarters · filed 2025-11-10 | $107.00M derived: sum of 3 quarters · filed 2025-11-10 | $107.00M 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $10.00M 10-Q · filed 2023-11-03 | $107.00M derived: sum of 2 quarters · filed 2023-11-03 | $107.00M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $97.00M 10-Q · filed 2023-08-09 | $97.00M 10-Q · filed 2023-08-09 | ||
| 2021-12-31 | $104.00M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |